Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 950,000 | 142.2% |
| Gross Profit | 860,000 | 117.8% |
| Cost of Revenue | 96,000 | 27.8% |
| Operating expense | 1.6M | 30.3% |
| Net Income | 550,000 | 184.4% |
| EBITDA | 640,000 | 212.6% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 39M | 0.7% |
| Total Liabilities | 11M | 2.5% |
| Total Equity | 27M | 2.1% |
| Shares Outstanding | 12M | 0.2% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 380,000 | 44.5% |
EPS
Financial Highlights for TherapeuticsMD in Q2 '25
TherapeuticsMD reported a revenue of 950,000, which is a 142.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 860,000, marking a 117.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 96,000, a -27.8% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 1.6M, showing a 30.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 550,000, showing a 184.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 640,000, showing a 212.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for TherapeuticsMD with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
